SGLT2 Inhibitor Empagliflozin Found Safe, Effective for HFpEF in Landmark EMPORER-Preserved Trial
July 7th 2021Empagliflozin, already indicated to improve outcomes in patients with HFrEF, reduced risk of a composite of CV death or hospitalization for HF in adults HFpEF, marking a potential therapeutic milestone.
COVID-19 Vaccine Update: Coadministration, Myocarditis Risk, Adolescents, Foreign Vaccination
July 6th 2021The ACIP green lights mRNA vaccines with warning for myocarditis and pericarditis, says COVID-19 vaccine can be given on the same day as other common vaccines, advises COVID vaccine for all aged ≥12 yrs.